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1.1. Methods 26 
1.2. Chalcone Synthesis reaction 27 
The Claisen-Schmidt condensation typically involves equimolar quantities of the 28 







 Base + H2O
rt
 30 
Scheme S1. Chalcone synthesis by classic base-catalysed reaction (Claisen-Schmidt). 31 
 32 
1.3. KAZ3 structure characterization 33 
The structure of the formed chalcone was confirmed using an array of different 34 
analytical methods including nuclear magnetic resonance (NMR), mass spectroscopy 35 
(MS), Fourier transform infrared spectroscopy (FTIR) and thin layer chromatography 36 
(TLC). The 1H-NMR and 13C-NMR spectra were recorded on a 400 MHz super-37 
conducting Bruker Spectrometer at 30 °C. Tetramethylsilane (TMS) was used as an 38 
internal standard. Chemical shifts are reported in δ units relative to the TMS signal and 39 
coupling constants (J) expressed in Hertz (Hz).1H-NMR information is provided in the 40 
following format: number of protons, multiplicity, coupling constant (where necessary) 41 
and assignment. Multiplicities are reported as follow; s=singlet, d=doublet, t=triplet, 42 
q=quartet, dd=doublets of doublet, m=multiplet. Infrared spectra (IR) were recorded 43 
using potassium bromide disks on a Perkin-Elmer 298 Spectrophotometer. Mass 44 
spectra and Accurate mass were recorded on a Micromass Quattro II Low Resolution 45 
Triple Quadruple Mass Spectrometer (EPSRC National Mass Spectrometry Service 46 
Centre, Swansea UK). Melting points (uncorrected) were determined on a Gallenkamp 47 
melting point apparatus in open glass capillary tubes. Thin layer chromatography (TLC) 48 
was performed on Merck Aluminium Sheet Silica Gel 60f254 coated plates. The TLC 49 
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plates visualised under Multiband UVGL-58 UV-254/366 nm UV light and stained 50 
with 2,4-dinitrophenylhydrazine (DNP to stain for the carbonyl group) or iodine 51 
absorbed on sand or phosphomolybdic acid (PMA). Silica gel (Fluka Silica 60; standard 52 
30-45 µ fine grade 20-45 µ) was used for Flash Column Chromatography. Elemental 53 
analyses (CHN) were performed on a CE440 elemental analyser by Warwick Analytical 54 
Services and were within ± 0.4 % of the theoretical values, unless otherwise stated. 55 
 56 
1.4. Structural characterization of silica hosts 57 
The small angle X-ray scattering (SAXS) patterns of the mesoporous silica samples 58 
(MCM-41, SBA-15) were recorded on a Rigaku R-AXIS IV Imaging Plate Detector 59 
mounted on a Rigaku RU-H3R Rotating Copper Anode X-ray Generator (λ=1.54 Å). 60 
The pore structure of SBA-15 and MCM-41 silica samples was studied by means of N2 61 
adsorption-desorption isotherms at 77 K. The experiments were performed on an 62 
automated manometric instrument (Autosorb-1MP, Quantachrome Instruments) after 63 
outgassing the samples (~30 mg) at 250 oC overnight under high vacuum. BET areas 64 
were calculated by the pertinent approximation and consistency criteria [42], while the 65 
pore volumes of MCM-41 and SBA-15 samples were determined from the N2 uptake 66 
plateau value at high relative pressures (p/p0~0.96) by assuming that the adsorbed fluid 67 
has liquid N2 density. Pore size distributions were deduced by using the N2-silica 68 
QSDFT (Quenched Solid Density Functional Theory) kernels. 69 
 70 
1.5. Preliminary drug concentration determination  71 
A preliminary study was conducted to investigate the suitable drug concentration in the 72 
initial suspensions of mesoporous silica before conducting electrospraying or solvent 73 
impregnation as loading methods. SBA-15 (6 mg/mL) was suspended in different drug 74 
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solutions with three different drug concentrations (2 mg/mL, 6 mg/mL, 12 mg/mL). 75 
Both loading methods were applied on the prepared suspensions. The produced loaded 76 
formulations were analyzed for their drug content using UV spectrophotometry and 77 
drug crystallinity using XRD.  78 
 79 
1.6. Particle size distribution 80 
The particle size distributions of SBA-15, MCM-41, FS and the drug loaded 81 
formulations were analysed using laser diffraction size analysis (NanoBrook Omni 82 
Particle Sizer and Zeta Potential Analyzer, Brookhaven Instruments, UK). Two mg of 83 
each sample were suspended in 2 mL distilled water and were sonicated for 5 minutes. 84 
The particle size distribution was an average of five repetitions. The average values of 85 
D10, D50 and D90 were taken as the mean diameter.  The lognormal size distribution 86 
was used to determine the size uniformity by calculating the span value. The span value 87 
is a parameter that is used to assess the width of particle size distribution and was 88 
calculated using the following equation  89 
                 𝑆𝑝𝑎𝑛 =
𝐷90−𝐷10
𝐷50
                              [2] 90 
Where D10, D50 and D90 are the sizes for which 10 %, 50 % and 90 % of the 91 
population (distribution) lies below, respectively. The higher the span value, the wider 92 
the particle size distribution. 93 
 94 
1.7.  ζ-potential studies 95 
Zeta potential of the pristine and the drug loaded samples was measured in phosphate 96 
buffer saline (PBS) solution. The zeta potential values of the silica particles dispersions 97 
in acetone and ethanol were also measured.  All experiments were performed using 98 
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NanoBrook Omni Particle Sizer and Zeta Potential Analyzer (Brookhaven Instruments, 99 
UK) and were repeated three times. 100 
 101 
1.8.  Fourier transform infrared spectroscopy (FTIR) 102 
Chemical bonding and interactions of MCM-41, SBA-15, FS and the drug loaded 103 
formulations were investigated using Perkin Elmer FTIR (Perkin Elmer with the 104 
software Bruker Alpha Opus 27). The IR spectra were obtained using the ATR 105 
technique (attenuated total reflection) on diamond crystal over the range of 4000 - 400 106 
cm−1 after 30 scans with a resolution of 4 cm-1. 107 
 108 
1.9. HPLC analysis 109 
A Shimadzu HPLC system series LC-20A was used for drug quantification consisting 110 
of a LC-20AD module pump, a SIL-10ADVP auto sampler and a UV-Diode array 111 
detector adjusted at 346 nm. Elution was performed on a Discovery® HS C18 (15 cm 112 
x 4.6 mm, 5μm) column using acetonitrile: water (60:40 v/v) as the mobile phase with 113 
a flow rate of 1.0 mL/min and an injection volume of 90 μL at 346 nm. The calibration 114 
curve was linear (R2 =0.998) in the concentration range evaluated (0.5 - 4 μg/mL). 115 
 116 
2. Results  117 
2.1. KAZ3 Structure characterization  118 
The chemical structure of the drug is shown in figure S1. The purity of the product was 119 
determined by TLC and elemental analysis. The product was also characterized by 120 
proton & carbon-13 NMR, infrared spectroscopy and mass spectrometry. The trans 121 
geometry of the alkene double bond was confirmed using 1H NMR, where the alkene 122 
protons appeared as a characteristic set of two doublets between 6.0 - 8.0 ppm having 123 
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coupling constants between 15 and 20 Hz, typical of a trans isomer Figure S2A. 124 
Coupling constants for cis alkene protons are 5-12 Hz. Coupling constants indicate the 125 
interaction between nuclei transmitted through intervening electrons. Aromatic proton-126 
proton spin coupling constants gave information of whether the coupling protons are in 127 
ortho (Jab 7-10 Hz), meta (Jab 2-3 Hz) or para position (Jab 0-1 Hz) to each other.  The 128 
infrared spectrum of KAZ3 (Figure S2C) shows absorption bands at ~1650-1660 cm-1 129 
related to the α, β-unsaturated carbonyl group (=C–C=O), which is characteristic of 130 
chalcones. The vibration of the unsaturated C=C bond (enone group) resulted in an 131 
absorption peak at 1590 cm-1, while the absorption band of =C–H appeared at 3005 cm-132 
1. The variance in absorption of the carbonyl group of chalcones is due to the presence 133 
of the electron donating methoxy groups in the phenyl ring. The asymmetrical 134 
stretching of the C-O-C bond in the methyl ether groups appeared around 1260 cm-1 135 
with a symmetrical stretching band around 1020 cm-1. A distinct absorption at about 136 
1600 cm-1 is likely due to the presence of the aromatic carbon ring. The peaks in the 137 
range of 2800 cm-1 to 3000 cm-1 correspond to benzene C–H stretching. Mass spectra 138 
in low ionisation mode (EI, MALDI or FAB) gave either M+ or (M+1)+ peaks of 139 
appropriate m/z values with (M-CH3)+ as the common fragment, whereas methoxy 140 











Figure S1. Chemical structure of (E)-3-(4-methoxyphenyl)-1-(3,4,5- 150 
rimethoxyphenyl)-prop-2-en-1-one (KAZ3). 151 
Yellow crystals (1.96 g, 89%), TLC:Rf 0.54 (ethyl acetate/ petroleum ether 4:6), m/z [FAB+] (329 152 
[M+H]+, 100%), max (KBr) /cm-1 1653 (C=O), δH (CDCl3), 3.85 (3H, s, OMe), 3.95 ( 9H, s, 3xOMe), 153 
6.95 (2H, d, ArH), 7.25 (2H, s, ArH), 7.37 (1H, d, CH=CH, J=17Hz), 7.61 (2H, d, ArH) 7.80 (1H, d, 154 
CH=CH, J=17Hz); C (CDCl3), 55.4, 56.4, 61.0, 106.2, 114.5, 119.5, 127.7, 130.2, 133.9, 142.4, 144.6, 155 
153.2, 157.5, 161.8, 189.3 (C=O); HRMS found [M+H]+ 329.1387, C18H17O5 requires [M+H]+ 156 





































































2.2.  Structural characterization of porous carriers 191 
X-ray diffractograms (Figure S3) show that SBA-15 demonstrated three well resolved 192 
peaks, including an intense peak at 0.86° assigned to (10) diffraction, as well as two 193 
weaker peaks at 1.46° and 1.68° which are indexed to (11) and (20) diffractions, 194 
respectively, suggesting long-rage order. MCM-41 exhibited four distinct peaks; a 195 
strong peak at 2.18°, which corresponds to (10) diffraction and three weaker peaks at 196 
3.72°, 4.28° and 5.72°, assigned to (11), (20) and (21) diffractions respectively, 197 
indicating a well-defined hexagonally ordered mesoporous structure. The structural 198 
parameters of the samples are summarized in Table S1. The nitrogen adsorption-199 
desorption isotherms of both SBA-15 and MCM-41 samples Figure S3 were of type IV 200 












Figure S3. Small angle PXRD patterns of A. SBA-15 and B. MCM-41. N2 adsorption 211 
(full symbols) – desorption (empty symbols) isotherms at 77 K of C. SBA-15 and D. 212 















































































































Table S1. Porous properties of the samples as determined from the N2 adsorption / 221 
desorption isotherms and structural parameters estimated from PXRD measurements. 222 
 SBET (m
2/g) TPV (cm3/g) D (nm) d10 (nm) a0 (nm) twall (nm) 
SBA-15 680 1.0 8 10.3 11.8 3.7 
MCM-41 1100 1.0 4 4.0 4.7 0.6 
SBET: BET area, TPV: total pore volume (at P/P0=0.96), D: mean pore diameter (using QSDFT method on the 223 
adsorption branch), d10: d spacing of the (10) reflections deduced from Bragg’s equation, a0: unit cell parameter for 224 
hexagonal symmetry according to the equation a0=2·d10/31/2, twall: pore wall thickness obtained by subtracting pore 225 
size from the unit cell parameter (twall=a0-D). 226 
 227 
2.3 Preliminary drug concentration determination  228 
A preliminary study was conducted to investigate the maximum drug content that can 229 
be loaded into mesoporous silica in the amorphous state using both loading methods 230 
(solvent impregnation and electrospraying).  XRD was used to evaluate the crystallinity 231 
of the drug loaded in the different formulations. XRD pattern of KAZ3 was also 232 
obtained (Figure S4 A) confirming the drug’s crystalline nature with four major 233 
diffraction peaks at 11.7 o, 17.3o, 21 o and 26.4 o.  234 
A maximum loading efficiency (35.6 %) was achieved when using drug concentration 235 
of 2 mg/ml for samples prepared using the solvent impregnation method. However, 236 
further increasing the drug concentration decreased the encapsulation efficiency. 237 
EHDA method was able to achieve a high encapsulation efficiency at all tested drug 238 
concentrations.  However, XRD analysis of electrosprayed formulations showed that 239 
the drug was entrapped in the amorphous form into the pores only when using drug 240 
concentrations of 2 mg/ml (Figure S4 B). A higher crystallinity in the produced 241 
formulations was observed by increasing the drug concentration to 6 mg/ml or 9 mg/ml. 242 
For the solvent impregnation method, increasing the drug concentration more than 2 243 
mg/ml resulted in an increase in drug crystallinity in the resulting formulations (Figure 244 
S4 C). It can be concluded that a complete pore filling was achieved when suspending 245 
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mesoporous silica in drug solution of 2 mg/ml.  As a result, 2 mg/ml was chosen as the 246 
initial drug concentration and 25 % w/w was set as a target loading for both loading 247 
methods.  248 
 249 
Table S2. Encapsulation efficiency at different drug concentrations and drug to 250 














2 1:3 (25 %) 35.6 ± 3.2 
Solvent  
impregnation 
6 1:1 (50 %) 28.8 ± 0.14 
Solvent  
impregnation 
12 2:1 (66.6 %) 21.0 ± 1.2 
Electrospraying 2 1:3 (25 %) 91.7 ± 0.4 
Electrospraying 6 1:1 (50 %) 93.8 ± 16.6 
 






























Figure S4. A. XRD pattern of pure KAZ3. Effect of initial drug concentration on the 278 
XRD patterns of KAZ3 loaded mesoporous silica using different drug loading methods 279 







2.4 SEM  282 
SEM images of the pristine silica particles and the prepared formulations are shown in 283 
Figure S5. SBA-15 (Figure S5 A) demonstrated rod-like particles with a diameter of 284 
approximately 0.45 μm and a length of ~1.1 μm. The resulting particulates showed an 285 
affinity to form longer fiber-like structures with lengths up to 10 - 22 μm. MCM-41 286 
(Figure S5 F) exhibited compact, rough and irregular shaped particles (0.5-1 μm), as 287 
well as fiber-like structures, as in the case of pristine SBA-15. Non-porous FS (Figure 288 
S5 K) consisted of small irregular shaped particles (0.1 - 0.5 μm) that tend to 289 




Figure S5. Scanning electron microscope images of A. SBA-15, B. SBA-Eth-SIM, C. 292 
SBA-AC-SIM, D. SBA-AC-SP, E. SBA-Eth-SP, F. MCM-41, G. MCM-AC-SIM, , H 293 
MCM-Eth-SIM, I MCM-AC-SP, J)MCM-Eth-SP, k FS, L FS-AC-SIM, M FS-Eth-294 
SIM, N FS-AC-SP, O FS-Eth-SP at 20 kX magnification. SBA: SBA-15, 295 
MCM=MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent 296 





2.5 Particle size distribution 300 
Particle size distributions of the silica materials before and after drug loading are shown 301 
in Figure S6, while the corresponding data (including average particle size and span 302 
value) are given in Table S3. Particle size deduced from DLS analysis appeared smaller 303 
compared to that obtained using SEM, which is most likely due to the sonication 304 
process performed prior to DLS measurements. The results demonstrated that 305 
electrosprayed mesoporous silica particles (SBA-15 and MCM-41) are nearly uniform 306 
in size (span ≤ 0.073) exhibiting smaller particle sizes than raw silica, effect attributed 307 
to the impact of atomization of merged fiber-like structures. The mean particle size of 308 
pristine SBA-15 and MCM-41 was 1231 and 1611 nm, respectively, whereas for 309 
electrosprayed formulations (e.g. SBA-Eth-SP and MCM-Eth-SP), the mean particle 310 
size was 535 and 409 nm, respectively. However, the size of electrosprayed non-porous 311 
silica formulations (e.g. FS-AC-SP) appeared to be greater than raw particles due to the 312 
presence of the dispersed drug crystals, which enhanced particle cohesiveness. 313 
Formulations prepared using solvent impregnation (SBA-Eth-SIM, MCM-Eth-SIM 314 
and FS-AC-SIM) exhibited increased mean particle sizes of 2091, 2463 and 2496 nm, 315 
respectively. In addition, the values D90 of  for these particles were 6085, 6811 and 316 
7100 nm, respectively. This increase in particle size and polydispersity (span value ≤ 317 























Figure S6. Particle size distribution of A. SBA-15, B. MCM-41 and C. FS based 339 
formulations before and after drug loading.  SBA: SBA-15, MCM: MCM-41, FS: 340 
fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation method and SP: 341 
electrospraying method. 342 

























































Table S3. Particle size distribution and ζ-potential of different silica particles before 344 











































SBA-15 1215 1225 1255 1231 0.03 -42.64 ± 13.72 
SBA-AC-SIM 320 400 7600 2773 18.20 -26.05 ± 6.55 
SBA-Eth-SIM 90 100 6085.
65 
2091 59.95 -17.57 ± 5.05
SBA-AC-SP 725 750 780 751 0.07 17.88 
SBA-Eth-SP 525 535 547 535 0.04 21.36 ± 3.41 
MCM-41 1310 1625 1900 1611 0.36 -54.86 ± 12.97 
MCM-AC-SIM 130 170 6900 2400 39.82 -24.0 ± 5.2 
MCM-Eth-SIM 250 330 6811 2463.73 19.88 -22.7 ± 17.4 
MCM-AC-SP 517 530 536 527.66 0.03 27.26 ± 3.75 
MCM-Eth-SP 403 410 414 409 0.02 23.57 ± 12.03 
Fumed silica 174 1425 1750 1116.34 1.10 -34.08 ± 13.7 
FS-AC-SIM 160 230 7100 2496.67 30.17 -13.45 ± 1.51 
FS-Eth-SIM 4610 5000 5370 4993.33 0.15 -12.76 ± 0.99 
FS-AC-SP 420 3200 3800 2473.33 1.05 2.68 ± 5.72 
FS-Eth-SP 465 1650 1830 1315 0.82 3.94 ± 9.28 
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2.6 ζ-potential studies 374 
Plain SBA-15, MCM-41 and FS nanoparticles exhibited negative zeta potential owing 375 
to the negatively charged silanol groups (SI, Table S4). The ζ-potential values of SBA-376 
15 and MCM-41 nanoparticles were highly negative (-42.64 mV and -54.86 mV, 377 
respectively), compared to that of the non-porous FS material (-34.08 mV) [1]. This is 378 
attributed to the greater surface area of their mesostructure and thus greater exposure to 379 
silanol groups of SBA-15 and MCM-41, when compared to non-porous FS. This 380 
suggests that SBA-15 and MCM-41 are highly reactive owing to the large number of 381 
surface accessible silanol groups, which are able to electrostatically interact with more 382 
drug molecules, hence achieving high drug loading [1]. KAZ3 loading increased the ζ-383 
potential values of all formulations but with variations arising due to the encapsulation 384 
method. This might be attributed to the interaction of silica’s silanol groups with the 385 
positively charged drug molecules. KAZ3 loading on MCM-41 particles using the 386 
solvent impregnation technique resulted to an increase in ζ-potential from -54.80 mV 387 
to -22.70 mV, whereas the use of electrospraying technique further increased the ζ-388 
potential values of the particles up to 27.26 mV, suggesting a greater interaction 389 
between the drug and silanol moieties when compared to the solvent impregnation 390 
method. Similar increase in ζ- potential of mesoporous silica particles upon drug 391 










Τable S4. ζ-potential of the different types of silica particle dispersions in different 400 
solvents. 401 
SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation method 402 
and SP:  electrospraying method * The separating line between stable and unstable dispersions is normally taken at 403 
either +30 or -30 mV.  Dispersions with ζ-potential beyond the range of ± 30 was considered stable. 404 
 405 
2.7  FTIR studies 406 
 FTIR analysis was performed to study the effect of drug loading on the chemical 407 
structure or interactions developed between the drug and silica. FTIR spectra (Figure 408 
S7) of SBA-15, MCM-41 and FS showed a broad peak at 3420 cm-1 that corresponds 409 
to O–H stretching vibration of the free silanol groups, while the intense peak in the 410 
range of 1000-1100 cm-1 is assigned to the stretching vibrations of the Si–O bond [3]. 411 
The FTIR spectra of drug-loaded formulations showed all the characteristic drug peaks 412 
corresponding to the enone group. This suggests that the chemical structure of KAZ3 413 
is not affected by the electrospraying process. Nevertheless, the decreased intensity and 414 
the disappearance of some peaks could be attributed to the dilution effect of silica 415 
particles. The FTIR spectra of physical mixtures revealed similar trends, confirming 416 
that the reduced peak intensity is indeed due to the dilution effect of the silica particles. 417 
The intensities of the peaks corresponding to silanol O–H appear decreased for the 418 





SBA-15 Acetone -9.7 ± 6.5 Unstable 
SBA-15 Ethanol 




-0.9 ± 6.4 
 
Unstable 
MCM-41 Ethanol -50.7 ± 4.5 Stable 
FS Acetone -36.7 ± 12.5 Stable 
FS Ethanol -35.6 ± 9.1 Stable 
21 
 
atomized drug loaded formulations as shown in the insert (Figure S7), suggesting that 419 
the quantity of free silanol groups has decreased due to their possible interactions with 420 
the drug. The reduction or absence of silanol O–H peak intensity due to its consumption 421 
during the interaction with the loaded drug or surface functional groups has been 422 






































































































Figure S7.  FTIR structure analysis of pure KAZ3 and A. SBA-15, B. MCM-41 and C. 462 
fumed silica before and after drug loading, SBA: SBA-15, MCM: MCM-41, FS: fumed 463 
silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation method and SP:  464 
















































































































Figure S8.  TGA analysis of pure KAZ3 and A. SBA-15, B. MCM-41 and C. fumed 487 
silica before and after drug loading.  SBA: SBA-15, MCM: MCM-41, FS: fumed silica, 488 
Eth: Ethanol, AC: acetone, SIM: solvent impregnation method and SP:  electrospraying 489 
method 490 
 491 
Table S5.  Melting points, melting enthalpies and degree of crystallinity obtained from 492 
DSC analysis of physical mixtures of KΑΖ3 with different types of silica particles 493 
(SBA-14, MCM-41 or FS) and their corresponding drug loaded formulations.  494 
 495 
Type of material 
 






SBA- KAZ3 physical mixture 98.1 135 100 
MCM- KAZ3 physical mixture 98.4  156.3 100 
FS-KAZ3 physical mixture 101.18  35 100 
SBA-AC-SIM 116 and 93 44.8 33.18 
SBA-Eth-SIM 116 107.2 79.40 
SBA-AC-SP 92.5 17.5 12.96 
SBA-Eth-SP - 0 0 
MCM-AC-SIM 108.2 62.8 40.17 
MCM-Eth-SIM 95.8 and 120 132 79.85 
MCM-AC-SP 94 24.5 14.82 
MCM-Eth-SP - 0 0 
FS-Eth-SIM 94.1 35 100.5 
FA-AC-SIM 98.8 17 42.5 
FS-AC-SP 94.1 24 60 
FS-Eth-SP 95.8 34 85 
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SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation 496 
method and SP:  electrospraying method 497 
 498 
The shift in drug’s melting peak in the physical mixtures from the original drug’s 499 
melting peak (101 °C) accounts for the entrapment of drug molecules within silica 500 
mesopores during the melting process of the DSC procedure. In contrast, the 501 
endothermic melting peak shown in thermograms for drug and nonporous silica 502 
physical mixture appears at the value identical to drug’s melting temperature. The 503 
decrease in peak sharpness for the three physical mixtures is due to dilution effect of 504 




Figure S9.  A., B., C. Higuchi square root of time plot for the release of KAZ3 from 507 
SBA -15, MCM-41 and FS based formulations, respectively. D., E., F. Korsmeyer- 508 
Peppas model for the in vitro KAZ3 release from SBA -15, MCM-41 and FS based 509 
formulations, respectively. SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: 510 
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Ethanol, AC: acetone, SIM: solvent impregnation method and SP: electrospraying 511 
method 512 
 513 

















SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation 531 











R² N R² kH R² kH 
SBA-AC-SIM 0.951 0.29 0.98 13.1 0.96 1.30 
SBA-ETH-SIM 0.967 0.26 0.96 7.9 0.98 0.94 
SBA-AC-SP 0.955 0.35 0.99 14.5 0.94 1.55 
SBA-Eth-SP 0.976 0.41 0.96 24.9 0.98 2.40 
MCM-AC-SIM 0.977 0.31 0.97 5.3 0.99 0.54 
MCM-Eth-SIM 0.962 0.26 0.98 2.9 0.98 0.64 
MCM-AC-SP 0.929 0.32 0.95 15.8 0.99 1.90 
MCM-Eth-SP 0.998 0.43 0.99 26.9 0.981 1.83 
FS-AC-SIM 0.964 0.27 0.94 4.3 0.91 1.15 
FS-Eth-SIM 0.972 0.26 0.96 2.0 0.911 0.32 
FS-AC-SP 0.911 0.26 0.91 5.3 0.91 0.88 
FS-Eth-SP 0.926 0.25 0.92 5.3 0.93 0.79 
28 
 
24h treatment 537 
 538 
   48h treatment 539 
 540 
Figure S10. Cellular morphology of Caco-2 cell cultures exposed to KAZ3. Phase 541 
contrast microscopic images (32x) of Caco-2 cells grown in the absence (control) or 542 
the presence of various concentrations (shown in each panel) of KAZ3 for 24 h and/or 543 





   KAZ3-loaded MCM-41 formulations 547 
 548 
  KAZ3-loaded SBA-15 formulations 549 
 550 
  KAZ3-loaded FS formulations 551 
 552 
Figure S11. Cellular morphology of Caco-2 cell cultures exposed to KAZ3-loaded 553 
MCM, SBA and FS formulations. Phase contrast microscopic images (32x) of Caco-2 554 
cell cultures grown A. without treatment (control culture) B. after treatment with 1 % 555 
Triton X-100 and C-N. after incubation with 0.1 mg/mL and 1 mg/mL of drug loaded 556 
MCM, SBA and FS materials for 48 h. [MCM-41, SBA-15: mesoporous silica 557 
30 
 
nanoparticles; FS: non porous fumed silica nanoparticles; SP: electrospraying method 558 
for drug loading; SIM: solvent impregnation method for drug loading. 559 
 560 
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